Pers Y-M, Ruiz M, Noël D, Jorgensen C
Inserm U1183, Hôpital Saint-Eloi, Montpellier, F-34295, France; Université Montpellier, UFR de Médecine, Montpellier, F-34000, France; Service d'immuno-Rhumatologie, Hôpital Lapeyronie, Montpellier, F-34295, France.
Inserm U1183, Hôpital Saint-Eloi, Montpellier, F-34295, France; Université Montpellier, UFR de Médecine, Montpellier, F-34000, France.
Osteoarthritis Cartilage. 2015 Nov;23(11):2027-35. doi: 10.1016/j.joca.2015.07.004.
Osteoarthritis (OA) is the most common form of degenerative arthritis, mainly characterized by the degradation of articular cartilage and associated with subchondral bone lesions. Novel therapeutic approaches for OA include cell-based therapies that have become thriving areas of research and development. In this context, mesenchymal stem or stromal cells (MSCs) have gained much interest based on their trophic and immunomodulatory properties that can help tissue repair/regeneration. The present review article discusses the interest of using MSCs in cell-therapy approaches with a focus on the mechanisms by which MSCs might exhibit a therapeutic potential in OA. Special attention is given to the anti-inflammatory function of MSCs and on miRNA modulation in OA for possible future innovative strategies. The paper also presents the current data on the undergoing MSCs-based clinical trials in OA.
骨关节炎(OA)是最常见的退行性关节炎形式,主要特征是关节软骨退化并伴有软骨下骨病变。OA的新型治疗方法包括基于细胞的疗法,这些疗法已成为蓬勃发展的研发领域。在这种背景下,间充质干细胞(MSCs)因其营养和免疫调节特性而备受关注,这些特性有助于组织修复/再生。本综述文章讨论了在细胞治疗方法中使用MSCs的意义,重点关注MSCs在OA中发挥治疗潜力的机制。特别关注了MSCs的抗炎功能以及OA中的miRNA调节,以探讨未来可能的创新策略。本文还介绍了目前正在进行的基于MSCs的OA临床试验数据。